CAR T Cell Therapy for Rheumatoid Arthritis

Area of Science:

• Immunology
• Cell Therapy
• Rheumatology

Background:

• Chimeric Antigen Receptor (CAR) T cell therapy has transformed B cell malignancies treatment.
• Emerging evidence suggests CAR T cell therapy's potential in autoimmune diseases, including rheumatoid arthritis (RA).

Purpose of the Study:

• To review current evidence on CAR T cell therapy for rheumatoid arthritis.
• To analyze case studies and preclinical research for RA treatment.

Main Methods:

• Analysis of ten rheumatoid arthritis patient case studies treated with CAR T cells targeting CD19/CD20 or BCMA.
• Review of in-vitro and animal model studies on engineered T cell subsets for RA.

Main Results:

• Nine of ten seropositive RA patients achieved remarkable responses, including B cell depletion, reduced autoantibodies, and drug-free remission.
• One seronegative patient initially responded but later relapsed.
• Preclinical studies explore targeting autoreactive B cells, T cells, or fibroblasts.

Conclusions:

• CAR T cell therapy demonstrates significant promise for refractory rheumatoid arthritis.
• Further research and large clinical trials are essential to validate efficacy and safety.